Legal & General Group
LCTX icon

Legal & General Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Legal & General Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Buy
+17,988
New +$24.9K ﹤0.01% 3052
2025
Q2 		– Sell
-15,644
Closed -$7.07K – 3478
2025
Q1 		$7.07K Hold
15,644
– – ﹤0.01% 3233
2024
Q4 		$7.86K Hold
15,644
– – ﹤0.01% 3291
2024
Q3 		$14.2K Hold
15,644
– – ﹤0.01% 3174
2024
Q2 		$15.6K Hold
15,644
– – ﹤0.01% 3127
2024
Q1 		$23.2K Hold
15,644
– – ﹤0.01% 2910
2023
Q4 		$17.1K Hold
15,644
– – ﹤0.01% 3094
2023
Q3 		$18.5K Hold
15,644
– – ﹤0.01% 3066
2023
Q2 		$22.1K Buy
+15,644
New +$21.6K ﹤0.01% 3080
2022
Q2 		– Sell
-9,674
Closed -$15K – 3597
2022
Q1 		$15K Hold
9,674
– – ﹤0.01% 3300
2021
Q4 		$24K Hold
9,674
– – ﹤0.01% 3214
2021
Q3 		$24K Hold
9,674
– – ﹤0.01% 3217
2021
Q2 		$28K Buy
+9,674
New +$25K ﹤0.01% 3162
2020
Q2 		– Sell
-13,751
Closed -$11K – 3436
2020
Q1 		$11K Sell
13,751
-7,419
-35% -$7.39K ﹤0.01% 3131
2019
Q4 		$19K Hold
21,170
– – ﹤0.01% 3201
2019
Q3 		$21K Hold
21,170
– – ﹤0.01% 3112
2019
Q2 		$23K Hold
21,170
– – ﹤0.01% 3145
2019
Q1 		$28K Buy
21,170
+9,379
+80% +$11.7K ﹤0.01% 2968
2018
Q4 		$11K Sell
11,791
-1,686
-13% -$2.58K ﹤0.01% 3255
2018
Q3 		$28K Sell
13,477
-3,941
-23% -$8.28K ﹤0.01% 3055
2018
Q2 		$31K Buy
17,418
+231
+1% +$465 ﹤0.01% 3002
2018
Q1 		$40K Sell
17,187
-8,281
-33% -$19.4K ﹤0.01% 2855
2017
Q4 		$48K Hold
25,468
– – ﹤0.01% 2878
2017
Q3 		$63K Buy
25,468
+5,762
+29% +$14.3K ﹤0.01% 2839
2017
Q2 		$54K Hold
19,706
– – ﹤0.01% 2898
2017
Q1 		$59K Sell
19,706
-767
-4% -$2.18K ﹤0.01% 2818
2016
Q4 		$65K Buy
20,473
+6,974
+52% +$21.4K ﹤0.01% 2797
2016
Q3 		$43K Hold
13,499
– – ﹤0.01% 2598
2016
Q2 		$30K Buy
+13,499
New +$33.1K ﹤0.01% 2736

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Legal & General Group's LCTX Position: Q2 2026 in Review

Legal & General Group opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 17,988 shares worth $23.6K. The stake represents ﹤0.01% of the portfolio and ranks #3052 among its holdings. This is a return to the name: Legal & General Group previously reported a position in LCTX as recently as Q1 2025.

Legal & General Group first reported a position in LCTX in Q2 2016 and has held it in 29 quarters since. The position peaked at $65K in Q4 2016. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Legal & General Group held 17,988 shares of Lineage Cell Therapeutics worth $23.6K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Legal & General Group position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3052 holding.
  • Legal & General Group first reported a position in Lineage Cell Therapeutics in Q2 2016 and has held it in 29 quarters since.
  • Legal & General Group's Lineage Cell Therapeutics position peaked at $65K in Q4 2016.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.